机构：[1]College of Biomedical Engineering, Sichuan University, Chengdu, Sichuan 610065, China.[2]Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.[3]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.四川大学华西医院[4]Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, Missouri 65409, United States.
the National Institutes of
Health (R01EY024072) (H.Y.), the Fundamental Research
Funds for the Central Universities (20822041D4094,
1082204112665), the National Natural Science Foundation
of China (52103177) (J.W.), and the Fundamental Research
Funds for the Central Universities (3332021106,
2019PT320028, 3332019100) (B.L.).
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]College of Biomedical Engineering, Sichuan University, Chengdu, Sichuan 610065, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Juan,Li Boxuan,Tang Jing,et al.Ionic Liquid Pilocarpine Analog as an Antiglaucoma Drug Candidate[J].ACS pharmacology & translational science.2022,5(9):752-760.doi:10.1021/acsptsci.2c00024.
APA：
Wang Juan,Li Boxuan,Tang Jing,Qiu Li,Qiao Xin...&Yang Hu.(2022).Ionic Liquid Pilocarpine Analog as an Antiglaucoma Drug Candidate.ACS pharmacology & translational science,5,(9)
MLA：
Wang Juan,et al."Ionic Liquid Pilocarpine Analog as an Antiglaucoma Drug Candidate".ACS pharmacology & translational science 5..9(2022):752-760
